Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back […]
Generative artificial intelligence’s biggest impacts on biotech are still to come. Learn more in our talk with Cradle Therapeutics’s co-founder, Elise de Reus.
Explore the latest in oncology R&D with Inpart’s new trends report, featuring emerging technologies, breakthrough innovations, and expert insights shaping the future of cancer research.
This week we talk with Immusoft CEO Sean Ainsworth to learn more about his journey in biotechnology and the work that Immusoft is doing in B-cell reprogramming